RxDoctor Payments Data

Jasmine Dorsey, MD

Internal Medicine · Battle Creek, MINPI 1205149325

Payments from drug & device makers

$2,056in general payments, 2019–2025

Across 118 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$434
  • Xeris Pharmaceuticals, Inc.$334
  • Amarin Pharma, Inc.$143
  • Pfizer$133
  • Astellas Pharma US Inc$112
  • Biohaven Pharmaceutical Holding Company Ltd.$105
  • plus $795 from 25 others

What the payments were for

  • Food & beverage$1,95695%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,056 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$114,586
Medicare patients
494
Services billed
2,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$38,241
EliquisApixaban56$28,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,381
JanuviaSitagliptin Phosphate11$11,461
FarxigaDapagliflozin Propanediol17$9,707
Breo ElliptaFluticasone/Vilanterol14$8,604
JardianceEmpagliflozin11$6,600
Atorvastatin Calcium159$2,638
Levothyroxine Sodium99$1,653
Omeprazole96$1,339
Pantoprazole Sodium78$1,214
Diclofenac Sodium25$1,170
Losartan Potassium83$1,129
Rosuvastatin Calcium64$1,015
Amlodipine Besylate116$1,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$434$38,24129 claims
PfizerEliquis$133$28,08156 claims
GSKTrelegy Ellipta, Breo Ellipta$13$27,98635 claims
MerckJanuvia$31$11,46111 claims
AstraZenecaFarxiga$39$9,70717 claims
Boehringer IngelheimJardiance$33$6,60011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →